Navigation Links
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Date:6/17/2009

potential of this Investigational New Drug to meet an unmet medical need, but it reflects on the design and integrity of the clinical development program of Epeius Biotechnologies. "It took years of sustained effort, but our decision to firmly establish the overall safety of repeated infusions of Rexin-G in early-stage clinical trials, before we moved on to progressively higher doses, has served us well," said Dr. Gordon. "For it was in determining the actual needs of our patients, in concordance with ongoing FDA guidance, that eventually achieved the control of tumor growth and metastasis," she added.

Remarkably, the adaptive designs of the strategic dose-escalation studies not only served to confirm the overall safety of Rexin-G and the lack of either systemic or dose-limiting toxicity, but it served to establish the critical thresholds of bioactivity and the dose-response relationships in several intractable cancers, which confirms and reveals the physiological mechanisms-of-action. These quantitative aspects of applied pharmacology are of paramount importance in establishing the clinical utility of a major new class of biological agents. Moreover, the progressive and adaptive trial designs helped to create and refine the clinical protocols for future medical praxis.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems that are embodied in Rexin-G and Reximmune-C, a tumor-targeted cancer vaccine. To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(LOGO 72dpi:

SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results
3. Ezra Van Gelder Joins Microchip Biotechnologies as Executive Vice President R&D
4. Veteran of the Beverage Industry, Ken Sadowsky, Joins Millennium Biotechnologies Board of Directors
5. MDS Analytical Technologies Acquires Blueshift Biotechnologies
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
10. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
11. Herzing University, Minneapolis Receives Board of Nursing Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... Javon Bea Mercy Health System ... as stroke capable by the State of Illinois, enabling ... Mercy Harvard Hospital. , The hospital was required to ... to treat stroke according to national standards of care ... patients to bypass hospitals not designated as an Emergent ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand in ... Vegas, Nevada for the annual ASD Market Week tradeshow. ... consumer-goods tradeshows and My Shiney Hiney will be one of ... Hiney can be found at booth number C1663. , My ... personal hygiene brush and cleansing system exclusively created to clean ...
(Date:2/27/2015)... 2015 A new study published in ... men who cycle on a regular basis and prostate cancer. ... suggests that the more hours per week a man spends ... leading to an increased importance on prostate cancer screening methods. ... look more closely at patents’ risk factors for developing prostate ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3
... of the tissue culture variety of anti-rabies vaccine, West ... the restricted nerve tissue variety vaccine till the demand-supply ... Surjyakanta Mishra told reporters here today that the Centre ... years ago citing side-effects., ,"However, since the demand-supply ...
... had affected more than 2.85 lakh population in parts of Karnataka ... , ,As against 1.20 lakh cases reported till April this ... in June so far, Minister for Health R Ashok said while ... that the government has failed to take urgent steps to contain ...
... suggests that the belief of being watched makes people behave more honestly, ... team monitored people dropping money in a canteen ... people put nearly three times more money when a poster ... poster showing flowers. , The poster might have ...
... Allison, a University of Alabama biostatistician has compiled a report ... was assisted in this venture by 19 other scientists in ... looked at more than 100 studies on the reasons for ... reasons could be an answer ,* Inadequate sleep: ...
... harassment and violence have become a way of life in ... name of combating Maoist guerrillas, say child rights activists here. ... of 36 rights organisations, says it has been urging the ... security forces from all occupied schools but to no avail. ...
... be the combination of dry eyes and mouth//, which lasts ... dry, gritty or burning eyes, intermittent blurry vision, a dry ... glands. The parotids are a pair of salivary glands behind ... and symptoms may include dry skin or vaginal dryness in ...
Cached Medicine News:Health News:Girl Students Sexually Harassed by Security Forces in Nepal 2
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)... 2015  PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the fourth quarter and full year ended ... transformative year for PTC. We are now a growing ... therapies in the rare disease space," stated Stuart W. ... are proud to bring the first treatment for Duchenne ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... and markets innovative proprietary products to treat voiding dysfunctions, ... Annual ROTH Conference on Tuesday, March 10, 2015. ... Reynolds , Chief Financial Officer, will present at 4:00 ... one at the conference at the Ritz Carlton in ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... COCOA, Fla., March 22, 2011 GeNO LLC ... technology company, today announced commencement of  the PHiano ... Treatment of Pulmonary Hypertension in patients with Pulmonary ... Idiopathic Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL™ nitric ...
... MADISON, Wis., March 22, 2011 ... two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) ... predictive tool for assessing the potential cardiotoxic effects of ... transitioning into a standard supply agreement.  Moving forward, iCell ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: